key: cord-0971296-t78jhkda
authors: Wang, Ping; Wang, Rong; Feng, Xue; Tang, Juanjuan; Zhang, Jiali
title: Assessment of elevated high-sensitivity troponin T to predict different mortality risks in patients with COVID-19
date: 2022-04-30
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2022.04.077
sha: f9fe0f42a5d4b847f58440558d0b9239aa9006c5
doc_id: 971296
cord_uid: t78jhkda

nan

Ping Wang a,b,1 *, Rong Wang a, 1 I have read the article entitled "Disinct etiologies of high-sensitivitity troponin T elevation predict different mortality risks for patients hospitalized with COVID-19" by Pegah Khaloo et al. [1] with great interest, recently published in this journal. The investigators reported that elevated high-sensitivitity troponin T (Hs-TnT) of distinct etiology in the context of COVID-19 was associated with a significantly increased mortality risk. Thanks a lot for the authors and the research. These findings implied that elevated Hs-TnT could be an additional and useful marker to predict mortality risks in patients hospitalized with COVID-19, especially in those with a primary cardiac etiology.

Data from China have shown that the high mortality rate in COVID-19 patients is associated with comorbid conditions [2] . Irawaty Djaharuddin et al. reported that hypertension, cardiovascular disease and diabetes were the most common comorbidity in patients' death due to COVID-19, and more than half of the patients had two or more comorbidities [3] . Firstly, the mortality rate was higher among elderly patients with COVID-19 and those with chronic comorbidities including chronic obstructive pulmonary, hypertension, diabetes and cardiovascular diseases [4] . Secondly, previous studies have indicated that cardiovascular events in patients with COVID-19 are associated with worse outcomes [5, 6] . The increased risk of cardiovascular events such as myocardial injury and heart failure in the context of COVID-19 infection might be associated by inflammation, endothelial dysfunction microvascular injury and hypoxemia 1 . Thirdly, Hs-TnT is the preferred biomarker for the detection of myocardial injury. Ozan M. Demir, et al. have found that Hs-TnT elevation does not represent major myocardial injury but acts as a sensitive integrated biomarker of global stress in most cases [7] . Several COVID-19 studies have often emphasized the association between elevated Hs-TnT concentrations and adverse events [8] . However, Hs-TnT elevation may be the consequence of a primary cardiac event or a secondary cardiac event provoked by non-cardiac illness such as pulmonary embolism, renal failure or sepsis [9].

In conclusion, Hs-TnT elevation alone is not a sufficient biomarker to predict different mortality risks in patients. Clinicians should combine Hs-TnT elevation in distinct etiologies, the age and comorbidities in patients with COVID-19 to predict

Distinct etiologies of high-sensitivity troponin t elevation predict different mortality risks for patients hospitalized with covid-19

Comorbidities and Mortality in covid-19 patients

Mortality-related risk factors of covid-19: A systematic review and meta-analysis of 42 studies and 423,117 patients

Covid-19 and cardiovascular disease: From Basic mechanisms to clinical perspectives

Association of cardiac injury with mortality in hospitalized patients with covid-19 in wuhan, china

Impact and determinants of high-sensitivity cardiac troponin-t concentration in patients with covid-19 admitted to critical care

The authors report no relationships that could be construed as s conflict of interest.